Search

Your search keyword '"Mairéad G. McNamara"' showing total 91 results

Search Constraints

Start Over You searched for: Author "Mairéad G. McNamara" Remove constraint Author: "Mairéad G. McNamara" Topic humans Remove constraint Topic: humans
91 results on '"Mairéad G. McNamara"'

Search Results

1. Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies

2. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma

3. Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes

4. Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma

5. High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent

6. The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases

7. Outcomes in older patients with biliary tract cancer

8. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy

9. Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)

10. Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer

11. Clinical and Translational Research Challenges in Biliary Tract Cancers

12. Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma

13. Molecular targeted therapies: Ready for 'prime time' in biliary tract cancer

14. Extrapulmonary poorly differentiated NECs, including molecular and immune aspects

15. Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives

16. Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review

17. Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer

18. Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary

19. Pancreatic Enzyme Replacement Therapy for Patients Diagnosed With Pancreaticobiliary Cancer: Validation of an Algorithm for Dose Escalation and Management

20. What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature

21. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis

22. Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis

23. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres

24. Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol

25. Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy

26. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials

27. Systemic therapies in elderly patients with advanced hepatocellular carcinoma: do not forget metronomic capecitabine

28. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis

29. Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis

30. Fibrolamellar carcinoma: Challenging the challenge

31. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials

32. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer

33. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)

34. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application

35. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study

36. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)

37. The Influence of Patientsʼ Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma

38. Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair

39. The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma

40. Neutrophil–lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival

41. Identification of areas for improvement in the management of bone metastases in patients with neuroendocrine neoplasms

42. Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer

43. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials

44. Outcomes in patients ≥ 80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy

45. A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome

46. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

47. Telotristat ethyl: a new option for the management of carcinoid syndrome

48. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems

49. Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound

50. Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers

Catalog

Books, media, physical & digital resources